YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

A Nishida; Y Takinami; H Yuki; A Kobayashi; S Akuzawa; T Kamato; H Ito; M Yamano; Y Nagakura; K Miyata

Abstract

YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

A Nishida, Y Takinami, H Yuki, A Kobayashi, S Akuzawa, T Kamato, H Ito, M Yamano, Y Nagakura and K Miyata

Journal of Pharmacology and Experimental Therapeutics September 1994, 270 (3) 1256-1261;

A Nishida

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Y Takinami

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

H Yuki

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

A Kobayashi

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

S Akuzawa

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

T Kamato

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

H Ito

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

M Yamano

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Y Nagakura

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

K Miyata

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Info & Metrics
eLetters
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics

Vol. 270, Issue 3

1 Sep 1994

Table of Contents
Table of Contents (PDF)
Index by author
Back Matter (PDF)
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

Message Subject (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics

Message Body (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Abstract

YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

A Nishida, Y Takinami, H Yuki, A Kobayashi, S Akuzawa, T Kamato, H Ito, M Yamano, Y Nagakura and K Miyata

Journal of Pharmacology and Experimental Therapeutics September 1, 1994, 270 (3) 1256-1261;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Abstract

YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

A Nishida, Y Takinami, H Yuki, A Kobayashi, S Akuzawa, T Kamato, H Ito, M Yamano, Y Nagakura and K Miyata

Journal of Pharmacology and Experimental Therapeutics September 1, 1994, 270 (3) 1256-1261;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Info & Metrics
eLetters
PDF

Main menu

User menu

Search

YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

Plain text

Vertical Tabs

Jump to comment:

In this issue

YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

Citation Manager Formats

Related Articles

Cited By...

Similar Articles

Navigate

More Information

ASPET's Other Journals